Alzheimer's Gene Therapy VY1706 Shows Strong Preclinical Safety, Tau Reduction; Voyager Eyes H2 2026 Clinical Trials
VYGR sits 63% above its 52-week low of $2.645.
Summary
Voyager Therapeutics presented compelling 3-month GLP toxicology data for VY1706, its investigational tau silencing gene therapy for Alzheimer's disease, at the ASGCT Annual Meeting. The data demonstrated that a single intravenous dose of VY1706 was well tolerated in non-human primates and achieved significant tau protein reductions of up to 64% in key brain regions. This positive preclinical safety and efficacy profile supports the company's timeline for an Investigational New Drug (IND) application in Q2 2026, with first-in-human dosing in Alzheimer's patients anticipated in H2 2026. For a small-cap biotech, this represents a significant de-risking event for a lead candidate in a major disease area, providing a clear path to clinical development. Traders will closely monitor the upcoming IND filing and the commencement of human trials as critical near-term catalysts.
At the time of this announcement, VYGR was trading at $4.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $250.7M. The 52-week trading range was $2.65 to $5.55. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.